<SEC-DOCUMENT>0001714899-26-000020.txt : 20260226
<SEC-HEADER>0001714899-26-000020.hdr.sgml : 20260226
<ACCEPTANCE-DATETIME>20260226160733
ACCESSION NUMBER:		0001714899-26-000020
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260226
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260226
DATE AS OF CHANGE:		20260226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Denali Therapeutics Inc.
		CENTRAL INDEX KEY:			0001714899
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				463872213
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38311
		FILM NUMBER:		26687906

	BUSINESS ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 866-8547

	MAIL ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dnli-20260226.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:a1df01bf-00d4-4d9d-a64f-d793f9a8fc7b,g:d0d7444e-12bb-4cda-8a6c-f344abbf0514,d:3d03ac8a7932416291a6975a5ca8d8bc-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dnli-20260226</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001714899</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dnli-20260226.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-26</xbrli:startDate><xbrli:endDate>2026-02-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3d03ac8a7932416291a6975a5ca8d8bc_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): </span></div><div style="margin-bottom:2pt;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">February&#160;26, 2026</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Denali Therapeutics Inc.</ix:nonNumeric></span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.774%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38311</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">46-3872213</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">161 Oyster Point Blvd.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94080</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">866-8547</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last reports)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.415%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.966%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol (s) </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">DNLI</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:111.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:13.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:381.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:32pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    &#9744;</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.639%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3d03ac8a7932416291a6975a5ca8d8bc_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02 &#160;&#160;&#160;&#160;Results of Operations and Financial Condition. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;26, 2026, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter ended December 31, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit&#160;99.1) shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.930%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991pressreleaseq42025.htm">Press Release dated February 26 2026.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL)</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3d03ac8a7932416291a6975a5ca8d8bc_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="text-align:justify;text-indent:37pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENALI THERAPEUTICS INC.</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Alexander O. Schuth</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander O. Schuth, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating and Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991pressreleaseq42025.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i4b32ae1a8fd34797b29bfb6b31b54cf0_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">99.1</font></div></div><div><img alt="denali_greenlogoa.jpg" src="denali_greenlogoa.jpg" style="height:52px;margin-bottom:5pt;vertical-align:text-bottom;width:249px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tividenofusp alfa (DNL310&#59; ETV&#58;IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndrome</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">DNL126 (ETV&#58;SGSH) Phase 1&#47;2 preliminary data presented at 2026 WORLD</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Symposium</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, supporting plans to pursue an accelerated approval path in Sanfilippo syndrome type A</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Start-up activities underway for DNL628 (OTV&#58;MAPT) Phase 1b study for Alzheimer's disease and DNL952 (ETV&#58;GAA) Phase 1 study for late-onset Pompe disease</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TransportVehicle</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform and clinical pipeline progressing across lysosomal storage disorders and neurodegenerative diseases</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SOUTH SAN FRANCISCO, Calif., &#8211; February&#160;26, 2026 &#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Denali Therapeutics Inc. (Nasdaq&#58; DNLI) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business highlights.</font></div><div id="i4b32ae1a8fd34797b29bfb6b31b54cf0_4"></div><div><font><br></font></div><div><font style="color:#222222;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;In 2025, we made meaningful progress toward delivering urgently needed treatment options for people living with neurodegenerative diseases and lysosomal storage disorders, building on the strong scientific foundation that defines Denali,&#8221; said Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics. &#8220;We established commercial readiness for the anticipated launch of tividenofusp alfa for individuals and families affected by Hunter syndrome and continued advancing our TransportVehicle platform across serious neurologic and systemic diseases that impact millions worldwide.</font></div><div><font><br></font></div><div><font style="color:#222222;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;In 2026, we are focused on launching tividenofusp alfa and transforming life for individuals living with other serious diseases. Data presented at WORLD</font><font style="color:#222222;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Symposium</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#222222;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">support our plans to pursue an accelerated approval path for DNL126 in Sanfilippo syndrome type A. We are also initiating clinical studies of DNL628 (OTV&#58;MAPT) in Alzheimer&#8217;s disease and DNL952 (ETV&#58;GAA) in late-onset Pompe disease. Over the next three years, we expect to advance four to six additional programs into the clinic, guided by our commitment to the patients we serve.&#8221;</font></div><div id="i4b32ae1a8fd34797b29bfb6b31b54cf0_7"></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fourth Quarter 2025 and Recent Program Updates</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLINICAL PROGRAMS</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tividenofusp alfa (DNL310&#59; ETV&#58;IDS) for Hunter syndrome (mucopolysaccharidosis type II &#91;MPS II&#93;)</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali has established commercial launch readiness in anticipation of a regulatory decision on the Biologics License Application (BLA) for tividenofusp alfa under the U.S. Food and Drug Administration (FDA) accelerated approval pathway with a Prescription Drug User Fee Act (PDUFA) target action date of April 5, 2026. Results from the open-label Phase 1&#47;2 clinical trial of tividenofusp alfa were published in the January 1, 2026 issue of </font><font style="background-color:#ffffff;color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The New England Journal of Medicine</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ongoing global Phase 2&#47;3 COMPASS study is expected to generate confirmatory evidence and support global regulatory submissions&#59; enrollment in Cohort A (neuronopathic participants) was completed in December 2025.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DNL126 (ETV&#58;SGSH)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">for Sanfilippo syndrome type A (MPS IIIA)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2026, Denali presented preliminary Phase 1&#47;2 data at WORLD</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Symposium</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> demonstrating treatment with DNL126 resulted in substantial reductions in disease biomarkers in cerebrospinal fluid (CSF heparan sulfate and GM3) and the periphery (urinary heparan sulfate) with a safety profile generally consistent with established enzyme replacement therapies. These preliminary data support an accelerated approval path in Sanfilippo syndrome type A. Planning for a global Phase 3 confirmatory study is ongoing.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TAK-594&#47;DNL593 (PTV&#58;PGRN) for </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GRN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-related frontotemporal dementia (FTD-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GRN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TAK-594&#47;DNL593 is an intravenously administered progranulin replacement therapy utilizing Denali&#8217;s Protein TransportVehicle</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (PTV) technology to deliver progranulin across the blood-brain barrier (BBB) and into the brain for individuals with FTD-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GRN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Enrollment in the ongoing Phase 1&#47;2 study is complete with a total of 40 participants with FTD-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GRN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> enrolled. Initial FTD-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GRN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patient data are expected in 2026. The program is being developed in collaboration with Takeda.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DNL952 (ETV&#58;GAA) for Pompe disease</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNL952 is enabled by Denali&#8217;s Enzyme TransportVehicle</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ETV) and designed to enhance delivery of the missing enzyme, GAA, into muscle tissues and across the BBB into the brain. In January 2026, Denali announced that the FDA had lifted the clinical hold on the Investigational New Drug (IND) application for DNL952. Phase 1 study start-up activities are underway.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DNL628 (OTV&#58;MAPT) for Alzheimer's disease</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNL628 is enabled by Denali&#8217;s Oligonucleotide TransportVehicle</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (OTV) and is designed to cross the BBB and reduce the tau protein by targeting the MAPT gene that encodes for tau. In January 2026, Denali announced that the Clinical Trial Application (CTA) for the Phase 1b study of DNL628 had been approved and study start-up activities are underway.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIIB122&#47;DNL151</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">small molecule</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LRRK2 inhibitor) for Parkinson&#8217;s disease </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical data readout of the global Phase 2b LUMA study of BIIB122 for early-stage Parkinson&#8217;s disease is expected in mid-2026. Denali&#8217;s Phase 2a BEACON study in LRRK2-associated Parkinson&#8217;s disease remains ongoing. The LRRK2 program is being developed in collaboration with Biogen.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SAR443122&#47;DNL758 (eclitasertib&#59; small molecule RIPK1 inhibitor) for ulcerative colitis</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 2 study of eclitasertib in participants with moderate to severe ulcerative colitis is expected to have results in the first half of 2026. The program is being developed by Sanofi.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IND-ENABLING STAGE PROGRAMS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali has multiple additional programs in the IND-enabling stage including DNL921 (ATV&#58;Abeta) for Alzheimer&#8217;s disease&#59; DNL111 (ETV&#58;GCase) for Parkinson&#8217;s disease and Gaucher disease&#59; DNL622 (ETV&#58;IDUA) for MPS I&#59; and DNL422 (OTV&#58;SNCA) for Parkinson&#8217;s disease.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Updates</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December, Denali announced two funding events. The first was a $275.0 million synthetic royalty funding agreement with Royalty Pharma plc based on future net sales of tividenofusp alfa. The second was a successful public offering of common stock and pre-funded warrants totaling approximately $200.0 million in net proceeds. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Participation in Upcoming Investor Conferences</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TD Cowen 46th Annual Healthcare Conference, March 2-4, 2026, Boston </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">UBS Biotech Summit Miami - Catalyst for Change, March 8-10, 2026, Miami</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leerink Global Healthcare Conference, March 8-11, 2026, Miami</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jefferies 2026 Biotech on the Beach Summit, March 10-11, 2026, Miami</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i4b32ae1a8fd34797b29bfb6b31b54cf0_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fourth Quarter and Full Year 2025 Financial Results</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net losses were $128.5 million and $512.5 million for the quarter and year ended December 31, 2025, respectively, compared to net losses of $114.8&#160;million and $422.8&#160;million for the quarter and year ended December 31, 2024, respectively.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses were $97.9&#160;million and $418.8&#160;million for the quarter and year ended December 31, 2025, respectively, compared to $99.8&#160;million and $396.4&#160;million for the quarter and year ended December 31, 2024, respectively. The increase of approximately $22.4 million for the year ended December 31, 2025, compared to the comparative period in the prior year was primarily attributable to higher external research and development costs related to multiple preclinical and clinical </font><font style="color:#222222;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TransportVehicle</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> programs, as well as increased personnel and other operating expenses associated with our large molecule manufacturing facility in Salt Lake City, Utah. These increases were partially offset by lower external expenses related to small molecule programs, which also contributed to the $1.9&#160;million decrease in research and development expenses for the quarter ended December 31, 2025, compared to the same period in the prior year.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $39.5 million and $136.6 million for the quarter and year ended December 31, 2025, respectively, compared to $30.1 million and $105.4 million for the quarter and year ended December 31, 2024, respectively. The increases of $9.4 million and $31.1 million for the quarter and year ended December 31, 2025, compared to the comparative period in the prior year were primarily driven by headcount increases and other activities associated with preparing for the potential commercial launch for tividenofusp alfa.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities were approximately $966.2 million as of December 31, 2025.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Denali Therapeutics</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform. With a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform the lives of people living with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i4b32ae1a8fd34797b29bfb6b31b54cf0_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali&#8217;s TransportVehicle</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (TV) platform and its therapeutics and commercial potential&#59; statements regarding Denali's business strategy and business plans, including expected key milestones for Denali's therapeutic portfolio in 2026 and beyond and Denali&#8217;s ability to execute on its commercial strategies&#59; plans, timelines and expectations related to Denali's Enzyme TransportVehicle</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ETV) franchise and its therapeutic and commercial potential&#59; plans, timelines and expectations relating to tividenofusp alfa (DNL310), including the timing, likelihood and scope of regulatory approvals and commercial launch, the therapeutic potential of tividenofusp alfa, and the likelihood of the Phase 2&#47;3 COMPASS data to support confirmatory evidence for global regulatory submissions and approval&#59; plans, timelines and expectations related to DNL126, including the timing and availability of data from the Phase 1&#47;2 study, the therapeutic potential of DNL126, the likelihood and pathway of regulatory approval, and the plans to initiate a Phase 3 study&#59; plans and expectations regarding DNL593 and the timing and availability of data from the ongoing Phase 1&#47;2 study&#59; plans and expectations regarding DNL628, including the planned Phase 1b study&#59; plans and expectations regarding DNL952, including the Phase 1 study and the program's therapeutic potential&#59; plans, timelines and expectations regarding DNL151, including the ongoing Phase 2a BEACON study, and timing and expectations for availability of data from the Phase 2b LUMA study&#59; expectations regarding DNL758 and the timing and availability of data from the Phase 2 study&#59; the timing and occurrence of potential milestone payments, including from Royalty Pharma plc&#59; Denali's future operating expenses and anticipated cash runway&#59; plans regarding participation in upcoming investor conferences&#59; and statements by Denali's Chief Executive Officer. All drugs currently being developed by Denali are investigational and have not received regulatory approval for any indication. Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to, risks related to&#58; the impact of adverse economic conditions, tariffs and inflation on Denali&#8217;s business and operations&#59; the occurrence of any event, change or other circumstance that could give rise to the termination of Denali&#8217;s agreements with Sanofi, Takeda, Biogen or other collaborators&#59; Denali&#8217;s transition to a late-stage clinical drug development company&#59; Denali&#8217;s and its collaborators&#8217; ability to complete the development and, if approved, commercialization of its product candidates&#59; Denali&#8217;s and its collaborators&#8217; ability to enroll patients in its ongoing and future clinical trials&#59; Denali&#8217;s reliance on third parties for the manufacture and supply of its product candidates for clinical trials&#59; Denali&#8217;s dependence on successful development of its blood-brain barrier platform technology and its programs and product candidates&#59; Denali&#8217;s and its collaborators' ability to conduct or complete clinical trials on expected timelines&#59; the risk that preclinical profiles of Denali&#8217;s product candidates may not translate in clinical trials&#59; the potential for clinical trials to differ from preclinical, early clinical, preliminary or expected results&#59; the risk of significant adverse events, toxicities or other undesirable side effects&#59; the uncertainty that product candidates will receive regulatory approval necessary to be commercialized&#59; Denali&#8217;s ability to continue to create a pipeline of product candidates or commercialize products&#59; developments relating to Denali's competitors and its industry, including competing product candidates and therapies&#59; Denali&#8217;s ability to obtain, maintain or protect intellectual property rights related to its product candidates&#59; implementation of Denali&#8217;s strategic plans for its business, product candidates and blood-brain barrier platform technology&#59; Denali's ability to obtain additional capital to finance its operations, as needed&#59; Denali's ability to accurately forecast future financial results and hedge against financial risk in the current environment&#59; and other risks and uncertainties, including those described in Denali's most recent Annual Report and Quarterly Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 27, 2025 and November 6, 2025, and Denali&#8217;s future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali&#8217;s expectations, except as required by law.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i4b32ae1a8fd34797b29bfb6b31b54cf0_16"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share amounts)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,905&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,787&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">418,778&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">396,440&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,460&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,059&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136,564&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,438&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137,365&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,846&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">555,342&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501,878&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from divestiture of small molecule programs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,537&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137,365)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(129,846)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(555,342)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(487,341)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,918&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,161&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,904&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,636&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(128,447)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114,685)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(512,438)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(422,705)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(128,549)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114,753)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(512,540)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(422,773)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.73)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.67)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.97)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.57)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175,458,962</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170,086,146</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172,649,097</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164,473,772&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i4b32ae1a8fd34797b29bfb6b31b54cf0_19"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.146%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205,326&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174,960&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">662,553&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">657,371&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,779&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,105&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900,658&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">864,436&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,322&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359,373&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,402&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,236&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease right-of-use asset</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,531&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,533&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,002&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,861&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,939&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,741&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,144,854&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,374,180&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity </font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,330&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,137&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95,021&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,071&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,351&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102,208&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liability, less current portion</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,210&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,673&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease liability, less current portion</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,532&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,615&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,093&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144,496&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,013,761&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,229,684&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,144,854&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,374,180&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laura Hansen, Ph.D.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hansen&#64;dnli.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Media Contact&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Erin Patton</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">epatton&#64;dnli.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>dnli-20260226.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:a1df01bf-00d4-4d9d-a64f-d793f9a8fc7b,g:d0d7444e-12bb-4cda-8a6c-f344abbf0514-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dnli="http://www.denalitherapeutics.com/20260226" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.denalitherapeutics.com/20260226">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20260226_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20260226_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.denalitherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>dnli-20260226_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:a1df01bf-00d4-4d9d-a64f-d793f9a8fc7b,g:d0d7444e-12bb-4cda-8a6c-f344abbf0514-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_48b4c7f2-b594-4afe-aab6-54384d3236fe_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_38b3e993-484c-4014-afea-ea978a09ec6f_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3af0cb1d-9fec-49b1-a929-919b7832164e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_47e3e01a-3161-4ff7-9222-fe1767c4c3d4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_a938bb45-b5e0-47b4-8437-6f700f17d6e7_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_771a855e-c8b7-4f34-b7b9-51110b83532e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b4aba002-9bd9-4278-96de-518eadb55b60_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_a9c2b944-6585-45c5-9281-ee81db38af18_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_38412261-a6d7-48f2-b31b-70bad5346334_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9eb6d04d-f485-4c91-9348-146c7a154452_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_66b2a449-434d-40f4-a2bf-222727229461_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ec4aac90-5f05-48f1-88f1-705f4bcbd32c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_45243c95-e0be-4c73-af65-ffbcfb25d45e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_71e37c90-b22e-4700-8ac7-dfa2f76146f8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6b72b935-b875-4455-b23b-9b43f65b086a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b80641f9-40df-42e2-b019-bb1bbe417085_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_dbcfc66a-fb3f-4310-b9ad-b180c2888fd8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_473272df-ab31-4b14-8eea-54c7921249fc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c6dedce7-a6b1-4912-af7c-1a21c0b810b2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3d895ce6-49e2-4366-ace9-374e861d0101_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_886ef086-f27f-4bc5-8362-3239896db6eb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b4d8c92a-b63b-4e15-a95c-119992fb2755_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>dnli-20260226_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:a1df01bf-00d4-4d9d-a64f-d793f9a8fc7b,g:d0d7444e-12bb-4cda-8a6c-f344abbf0514-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/Cover" xlink:type="simple" xlink:href="dnli-20260226.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d5160d5d-7529-4b3c-bc81-916255f48b22" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_DocumentType_d5160d5d-7529-4b3c-bc81-916255f48b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_59dd2cd5-4432-41be-8bd2-c3b59d51a70f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_DocumentPeriodEndDate_59dd2cd5-4432-41be-8bd2-c3b59d51a70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_70bd6e29-88c4-4c01-90bf-6747ebd62759" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_EntityRegistrantName_70bd6e29-88c4-4c01-90bf-6747ebd62759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0a7569da-0778-47a5-b082-4361e7bf3a89" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0a7569da-0778-47a5-b082-4361e7bf3a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e74553a8-547e-408a-ba6f-1076663d4dee" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_EntityFileNumber_e74553a8-547e-408a-ba6f-1076663d4dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8e7f7704-f791-4a8e-b386-e2643a8dbc21" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_EntityTaxIdentificationNumber_8e7f7704-f791-4a8e-b386-e2643a8dbc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6f9411c3-ed95-44dd-aa82-152671fcd370" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_EntityAddressAddressLine1_6f9411c3-ed95-44dd-aa82-152671fcd370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_72570b25-9799-4201-8e8e-e3c866b46d22" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_EntityAddressCityOrTown_72570b25-9799-4201-8e8e-e3c866b46d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8fee2ec1-e9c4-410e-b9cc-1591e0b54254" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_EntityAddressStateOrProvince_8fee2ec1-e9c4-410e-b9cc-1591e0b54254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_32dc1cd0-bc8c-4bea-b8a8-ff3e6af136dd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_EntityAddressPostalZipCode_32dc1cd0-bc8c-4bea-b8a8-ff3e6af136dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fd605c02-8798-487f-bbf7-6ff106f74a30" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_CityAreaCode_fd605c02-8798-487f-bbf7-6ff106f74a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_aa4467ed-9169-455a-ad80-9bab026a3104" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_LocalPhoneNumber_aa4467ed-9169-455a-ad80-9bab026a3104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_3103e1c3-de9e-4abd-8df2-42e300d4b963" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_WrittenCommunications_3103e1c3-de9e-4abd-8df2-42e300d4b963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_80093d02-2d3c-4eb6-8fe4-05ed9f992c13" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_SolicitingMaterial_80093d02-2d3c-4eb6-8fe4-05ed9f992c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_8367b370-cddd-4ce3-a6e5-97adea399fb0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_PreCommencementTenderOffer_8367b370-cddd-4ce3-a6e5-97adea399fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_e24586f3-78e1-4832-9835-d8ff2a557143" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_e24586f3-78e1-4832-9835-d8ff2a557143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_bb7373a0-8859-4216-8dad-3bf39fb1d448" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_EntityEmergingGrowthCompany_bb7373a0-8859-4216-8dad-3bf39fb1d448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_afb341c3-a59c-4c7c-9602-33fe2b124d5c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_Security12bTitle_afb341c3-a59c-4c7c-9602-33fe2b124d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f5d1a7d8-2186-4291-988d-049b226a6b9b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_TradingSymbol_f5d1a7d8-2186-4291-988d-049b226a6b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_18fed6cd-3306-44aa-bcb8-f7b5b4445ca7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_SecurityExchangeName_18fed6cd-3306-44aa-bcb8-f7b5b4445ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_30670d1c-4cfd-4247-baf7-e70c9b9d62fb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_EntityCentralIndexKey_30670d1c-4cfd-4247-baf7-e70c9b9d62fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4562d8c8-49b2-4138-8caa-1848fea86c42" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_11535cd4-08a2-4981-b156-c41b1b99c3e8" xlink:to="loc_dei_AmendmentFlag_4562d8c8-49b2-4138-8caa-1848fea86c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>denali_greenlogoa.jpg
<TEXT>
begin 644 denali_greenlogoa.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_X@_P24-#7U!23T9)3$4  0$   _@87!P
M; (0  !M;G1R4D="(%A96B 'Z0 +  0 !P 5 #AA8W-P05!03     !!4%!,
M                        ]M8  0    #3+6%P<&P
M                                             !%D97-C   !4
M &)D<V-M   !M   !+QC<')T   &<    "-W='!T   &E    !1R6%E:   &
MJ    !1G6%E:   &O    !1B6%E:   &T    !1R5%)#   &Y   " QA87)G
M   .\    "!V8V=T   /$    #!N9&EN   /0    #YM;6]D   /@    "AV
M8V=P   /J    #AB5%)#   &Y   " QG5%)#   &Y   " QA86)G   .\
M "!A86=G   .\    "!D97-C          A$:7-P;&%Y
M
M                                ;6QU8P         G    #&AR2%(
M   4   !Y&MO2U(    ,   !^&YB3D\    2   "!&ED       2   "%FAU
M2%4    4   "*&-S0UH    6   "/'-L4TD    4   "4F1A1$L    <   "
M9FYL3DP    6   "@F9I1DD    0   "F&ET250    8   "J&5S15,    6
M   "P')O4D\    2   "UF9R0T$    6   "Z&%R       4   "_G5K54$
M   <   #$FAE24P    6   #+GIH5%<    *   #1'9I5DX    .   #3G-K
M4TL    6   #7'IH0TX    *   #1')U4E4    D   #<F5N1T(    4   #
MEF9R1E(    6   #JFUS       2   #P&AI24X    2   #TG1H5$@    ,
M   #Y&-A15,    8   #\&5N054    4   #EF5S6$P    2   "UF1E1$4
M   0   $"&5N55,    2   $&'!T0E(    8   $*G!L4$P    2   $0F5L
M1U(    B   $5'-V4T4    0   $=G1R5%(    4   $AG!T4%0    6   $
MFFIA2E     ,   $L !, $, 1  @ '4 ( !B &\ :@!ISNRW[  @ $P 0P!$
M $8 80!R &< 90 M $P 0P!$ $P 0P!$ "  5P!A '( ;@!A %, >@#M &X
M90!S "  3 !# $0 0@!A '( 90!V &X _0 @ $P 0P!$ $( 80!R '8 ;@!I
M "  3 !# $0 3 !# $0 +0!F &$ <@!V &4 <P!K .8 <@!M $L ; !E '4
M<@!E &X +0!, $, 1 !6 .0 <@!I "T 3 !# $0 3 !# $0 ( !A "  8P!O
M &P ;P!R &D 3 !# $0 ( !A "  8P!O &P ;P!R $P 0P!$ "  8P!O &P
M;P!R $$ 0P!, "  8P!O '4 ; !E '4 <B / $P 0P!$ " &109$!D@&1@8I
M!!H$/@0[!$P$/@1 !#X$,@0X!#D ( !, $, 1" / $P 0P!$ " %Y@71!>(%
MU07@!=E?:8)R $P 0P!$ $P 0P!$ "  30#@ '4 1@!A '( 90!B &X _0 @
M $P 0P!$!"8$,@0U!$($/00^!#D ( 06!!H +00T!#@$000_!#L$-00Y $,
M;P!L &\ =0!R "  3 !# $0 3 !# $0 ( !C &\ =0!L &4 =0!R %< 80!R
M &X 80 @ $P 0P!$"3 ) @D7"4 )*  @ $P 0P!$ $P 0P!$ " .*@XU $P
M0P!$ "  90!N "  8P!O &P ;P!R $8 80!R &( +0!, $, 1 !# &\ ; !O
M '( ( !, $, 1 !, $, 1  @ $, ;P!L &\ <@!I &0 ;P!+ &\ ; !O '(
M( !, $, 1 .( [,#QP/! \D#O .W " #OP.X \P#O0.W "  3 !# $0 1@#D
M '( 9P M $P 0P!$ %( 90!N &L ; !I "  3 !# $0 3 !# $0 ( !A "
M8P!O '( 90!S,*LPZ3#\ $P 0P!$=&5X=     !#;W!Y<FEG:'0@07!P;&4@
M26YC+BP@,C R-0  6%E:(        /-1  $    !%LQ865H@        @]\
M #V_____NUA96B        !*OP  L3<   JY6%E:(        "@X   1"P
MR+EC=7)V        !      %  H #P 4 !D '@ C "@ +0 R #8 .P!  $4
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MWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW__W!A<F$
M  ,    "9F8  /*G   -60  $]    I;=F-G=          !  $
M 0    $          0    $          0  ;F1I;@         V  "N%
M4>P  $/7  "PI   )F8   ]<  !0#0  5#D  C,S  (S,P ",S,
M &UM;V0        &$   H%+]8FUB                          !V8V=P
M       #     F9F  ,    "9F8  P    )F9@    (S,S0      C,S-
M   ",S,T /_N  Y!9&]B90!D      '_VP!#  P("!L*&R(1%R0J)!P;("0K
M*"@@)"DE)3$O)2DN*BLK.2LJ+B\T-34U-"\[.SL[.SL[.SL[.SL[.SL[.SL[
M.SO_VP!# 0T+"Q .$!L4&R0R*"$H,CLT,C(R.SL[.SL[.SL[.SL[.SL[.SM
M0$! 0#M 0$! 0$! 0$! 0$! 0$! 0$! 0$#_VP!# @T+"Q .$!L4&R0R*"$H
M,CLT,C(R.SL[.SL[.SL[.SL[.SL[.SM 0$! 0#M 0$! 0$! 0$! 0$! 0$!
M0$! 0$#_P  1" '%"&$# "(  1$! A$"_\0 'P   04! 0$! 0$
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M]?;W^/GZ_]H # ,   $1 A$ /P#U6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** *UY?+9H99"%5>I-<M<?$J-#A(V(]20O^-9/Q#U RRBW_
M (8P#^)Y_D17)XII$2EJ=]_PLU?^>1_[['^%'_"S5_YY'_OL?X5P.*,4[$\[
M.^_X6:O_ #R/_?8_PH_X6:O_ #R/_?8_PK@<48HL'.SOO^%FK_SR/_?8_P *
M=%\3(R<-&P^A!_F!7G^* <46#G9Z_I7B2'4^(V^;^Z>&_+_#BM/=7A\<AB(9
M205Z$=1^->E^#_$G]JJ8Y/\ 6IU]QG@_X_\ UZ31:D=/1112*"BBB@ HHHH
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MZ8'->&X[UV?AOQT8BL%R<@]'[\],TFBXR/0:*8K[N1SGTI](L**** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8/CD9LY?\
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MZ:BBBD6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >>_$S_61_[A_G7&UV7Q,_UD?^X?YUQM4C.6X4444$A1110 44
M44 =!X$_X^T^C_\ H)KU.O+/ G_'VGT?_P!!->IU+-(;"T444%!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6#XX_X\Y?^ ?^AK6]6#XX_P"/.7_@'_H:
MT">QY2:*#13,@HHHI@%%%% !6[X'_P"/R+_@?_H#5A5N^!_^/R+_ ('_ .@-
M0-;GJ]%%%2:GA=%2W=N;9VB;JI(_*HJHQ"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M4\.:N=*F67/RG ;Z'K6710&Q[DK9Y[4ZN=\%ZG]NMU!^]&=I_#!'Z'^==%4F
MR=PHHHH **** "BBB@ HHHH **** "BBB@ I*6J]]="T1I6Z(I/Y4 <'\0=:
M\YQ:+T09;ZD9 _ ?SKCS4MS<M<,TK'YF))_$YJ*J,I.["BBB@04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !0!10#0!ZYX0_P"/2+_=_J:V*R_#,!@MHD;J$'Z\_P!:U*DV"BBB@ HH
MHH **** "BBB@ HHHH **** $-8OBG5_[,@9Q]YOE7ZGO^%;5>:_$#4OM$X@
M!XB X[9/)_2@3=CEV)8DGO24451D%%%% !1110 4444 %%%% !1110 4444
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M&O7:Y?QYI/VR#S5'S1<_\![C\.OX4)DR5SS2BC&>:*HS"BBB@ HHHH ****
M.@\$ZO\ 8)PK'Y9?E/L>@/Y\?2O4LFO#@V.1UKUOPSJW]IP++_$!AOJO^-)E
MP9L4444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** //?B9_K(_]P_SKC:[+XF?ZR/_ '#_ #KC:I&<MPHHHH)"BBB@ HHH
MH Z#P)_Q]I]'_P#037J=>6>!/^/M/H__ *":]3J6:0V%HHHH*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "L'QQ_QYR_\ _\ 0UK>K!\<?\><O_ /_0UH
M$]CRDT4&BF9!1113 **** "MWP/_ ,?D7_ __0&K"K=\#_\ 'Y%_P/\ ] :@
M:W/5Z***DU$Q12T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ"TF7 6BEHI%B44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M%
M"44M% "8K,\0Z6-1@>,\G!*^S <5IT8H!GAE%.DX)^M-JC$**** "BBB@ HH
MHH ]7\$G-I'_ ,#_ /0VK=K!\#_\><7_  /_ -#:MZI-D%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444W- &3X@OO(38.
MK\?AZURM7-8O/M,A;L.!5.N"O/GD>IAJ7)#U%Q1BBBLC<2K&GW7V5PX[$@_0
MU7H/--.SN*45)6._63< 1T-.S6-X=O/.38>J<?AV-;->C"7-&YX\X.$F@IKQ
M!QM/0]:?15$GC?B#33ILS0GIGY?]T]#6?7H?Q TKSXA<J/FBX/\ NGC]#S7G
ME4C)JS"BBB@04444 %%%% !74> ]7^S3>0Q^67I]1T_/I^-<O3D<QD,.".GX
M4!>Q[CFC-9VA:J-3A6?N1R!ZC@C\_P!*T:DV%HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** //?B9_K(_]P_SKC:[+XF?ZR/_
M '#_ #KC:I&<MPHHHH)"BBB@ HHHH Z#P)_Q]I]'_P#037J=>6>!/^/M/H__
M *":]3J6:0V%HHHH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'QQ_Q
MYR_\ _\ 0UK>K!\<?\><O_ /_0UH$]CRDT4&BF9!1113 **** "MWP/_ ,?D
M7_ __0&K"K=\#_\ 'Y%_P/\ ] :@:W/5Z***DU"BBB@ HHHH **** "BBB@
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M *&M;U8/CC_CSE_X!_Z&M GL>4FB@T4S(****8!1110 5N^!_P#C\B_X'_Z
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M% 'J_@?_ (\XO^!_^AM6[6%X'_X\XO\ @?\ Z&U;M2;(**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH **** "BBB@#B/B9TB_X'_-*X*N]^)G2+_@?\TK@JI&<MPHHHH)"BBB@
MHHHH LZ9_K8_]]?YBO:A7BNF?ZV/_?7^8KVH4F7 6BBBD6%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 )1110!X=+U/UIM.EZGZTVJ,0HH
MHH **** "BBB@#U?P/\ \><7_ __ $-JW:PO _\ QYQ?\#_]#:MVI-D%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 )FH9[D0*7/0"I<5S_
M (EN\8A'KDU$Y\JN72ASR43"GE,Q+'JQIE%%>>]3UTK"T444AA1110 4444
M)6OX<L_-<R'HO\SR/TK(Q7::79_98PO?'/UK:A3O*YRXNKRPY>I=Q1BEHKN/
M."BBB@ HHHH **** ,CQ)I7]IP-%_%U7ZC_ZV1]#7D9&#C_/TKW'%>7^.=(^
MPS[U^[*"P] 1]X4T1-'.T444R HHHH **** "C-%% 'I7@+5_M</D-]Z+ _X
M"?N_ETKJ<UY#X9U;^S)UD)^4\-]#_AQ^5>N@YI,UB[H=1112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Y[\3/]9'_N'^=<;79?$S_61_[A_G
M7&U2,Y;A11102%%%% !1110!T'@3_C[3Z/\ ^@FO4Z\L\"?\?:?1_P#T$UZG
M4LTAL+11104%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8/CC_CSE_P"
M?^AK6]6#XX_X\Y?^ ?\ H:T">QY2:*#13,@HHHI@%%%% !6[X'_X_(O^!_\
MH#5A5N^!_P#C\B_X'_Z U UN>KT445)J%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q?Q+_ -7%_OG^
M5>?UZ!\2_P#5Q?[Y_E7G]4C.>X4444$A1110 4444 /M_O+]1_.O<:\.M_O+
M]1_.O<:3+AL%%%%(L**** "BBB@ HHHH **** "BBB@ KRKQU_Q]R?1/_0!7
MJM>5>.O^/N3Z)_Z *:)GL8%%%%,S"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /2?AS_Q[-_UU
M;_T%:ZH5ROPY_P"/9O\ KJW_ *"M=4*DU0M%%% PHHHH **** "BBB@ HHHH
M **** "BBB@#B/B9TB_X'_-*X*N]^)G2+_@?\TK@JI&<MPHHHH)"BBB@ HHH
MH LZ9_K8_P#?7^8KVH5XKIG^MC_WU_F*]J%)EP%HHHI%A1110 4444 %%%%
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M_4?SKW&DRX;!1112+"BBB@ HHHH **** "BBB@ HHHH *\J\=?\ 'W)]$_\
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M1>3_ $K/S^M=;H-G]G3/=L&M*$.>1SXFIR0OU9J[:,4M%>@>8%%%% !1110
M4444 %%%% !1110!S?C;2/[0@+*/GB^8>X[C\N:\OKW$IGBO(_$VE'3)VB'W
M2=R_[I_PIHB:,JBBBF0%%%% !1110 4444 >L>$]7_M.!7/WD^5OJ!U_$5MU
MY=X'U?[#/L8_)+\OT;L?YC\:]0-)FJ=T.HHHI#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#SWXF?ZR/_</\ZXVNR^)G^LC_ -P_SKC:I&<MPHHHH)"B
MBB@ HHHH Z#P)_Q]I]'_ /037J=>6>!/^/M/H_\ Z":]3J6:0V%HHHH*"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+%'^Q(/^>2?]\+_A1_8D'_/)/^^%_P *O44!8H_V)!_SR3_OA?\ "C^Q(/\
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M0 4444 6=,_UL?\ OK_,5[4*\5TS_6Q_[Z_S%>U"DRX"T444BPHHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+/ G_'VGT?\ ]!->IU+-(;"T444%!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6#XX_X\Y?\ @'_H:UO5@^./^/.7_@'_ *&M GL>4FB@T4S(****8!11
M10 5N^!_^/R+_@?_ * U85;O@?\ X_(O^!_^@-0-;GJ]%%%2:A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 <7\2_P#5Q?[Y_E7G]>@?$O\ U<7^^?Y5Y_51,Y[A11102%%%% !1110
M^W^\OU'\Z]QKPZW^\OU'\Z]QI,N&P4444BPHHHH **** "BBB@ HHHH ****
M "O*O'7_ !]R?1/_ $ 5ZK7E7CK_ (^Y/HG_ * *:)GL8%%%%,S"BBB@ HHH
MH *[+X:?ZR3_ '!_.N-KLOAI_K)/]P?SH8X[GH-+24M2:A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M37J=>6>!/^/M/H__ *":]3J6:0V%HHHH*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "L'QQ_QYR_\ _\ 0UK>K!\<?\><O_ /_0UH$]CRDT4&BF9!1113
M **** "MWP/_ ,?D7_ __0&K"K=\#_\ 'Y%_P/\ ] :@:W/5Z***DU"BBB@
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M_/1_^^C_ (T?VE+_ ,]'_P"^C_C187.>TYHS7BW]I2_\]'_[Z/\ C1_:4O\
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M?^ C=7KM>>_#>QW.\YZ*H4?5N3^@_6O0J3-(+0****104444 %%%% !1110
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MX$RAUY##(/L1FO$?>O1/A]JOGQ&V)^:(\?[I_P #^F*&BX,["BBBI+"BBB@
MHHHH **** "BBB@ HHHH Y'XCVQD@60?P.,_0@C^>*\YKV'Q%8_;H)(NY7CZ
MCD5X]FFC.>X4444R0HHHH **** #ISWKIO"OB_\ LL>1+S'G@\Y7\.XKF:*
M3LSVFPU..^7?$P8>W]1VJSFO#T<QG*G!'IQ4W]I2_P!]O^^C_C2L7SGM6:,U
MXM_:4O\ ST?_ +Z/^-']I2_\]'_[Z/\ C18.<]IS1FO%O[2E_P">C_\ ?1_Q
MH_M*7_GH_P#WT?\ &BP<Y[3FC->+?VE+_P ]'_[Z/^-']I2_\]'_ .^C_C18
M.<]IS1FO%O[2E_YZ/_WT?\:/[2E_YZ/_ -]'_&BP<Y[3FC->+?VE+_ST?_OH
M_P"-']I2_P#/1_\ OH_XT6#G/:<T9KQ;^TI?^>C_ /?1_P :/[2E_P">C_\
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M4 %8/CC_ (\Y?^ ?^AK6]6#XX_X\Y?\ @'_H:T">QY2:*#13,@HHHI@%%%%
M!6[X'_X_(O\ @?\ Z U85;O@?_C\B_X'_P"@-0-;GJ]%%%2:GALDID8N>K$D
M_CUIM%%48A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 48HK:\(Z+_:<XSRD>&;TX/ _'
MI^?I0.UV=]X2TS[!;HA^\PW-]6YQ^ K<INVG5)J%%%% !1110 4444 %%%%
M!1110 4444 %07=N+A6C;HP(/X\5/24 >)7EHUK(T+=48@_A_CU^E0UV?Q#T
M<JPO%Z-A6QV(Z'\1Q^ ]:XRJ1DU9A1110(**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HS110!Z_P"%
MIC-:Q,W78/TXK5K'\(?\>D7^[_4UL5)JM@HHHH&%%%% !1110 4444 %%%%
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M&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7ER]AU%%%=)RA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M><O_  #_ -#6MZL'QQ_QYR_\ _\ 0UH$]CRDT4&BF9!1113 **** "MWP/\
M\?D7_ __ $!JPJW? _\ Q^1?\#_] :@:W/5Z***DU/"Z***HQ"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***T='T";53B->.['A1^//Y=: 6I0BC,Q"J"23@ =:] \.>!A;;9Y^7'
M(7^$?7U/Z5JZ!X7CTD9'S2$<N1^@]!_/N:VRN:39HHBXI:**104444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !32G>G44 <QXI\*+J@\V/B8?DV.@
M/H?0UYK<0-;L8W!# X(/^?R]:]OQ61KWAR/6%PW#@<,.OT/J*:9$HGDE%:FL
M^'9M*/SC*]F7E?\ ZQ]CCVSUK+_STID:H**** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 )BD*YIU% 'DGBW2/[-G8
M81_F7TP3R/P-8U>F^.-(-]!O49>(EOJ/XA_(_A7F7\JI&35F%%%% @HHHH *
M*** "M[P9J_]GS@'[DHVGT'/!_/]*P:.E ;'N:G-+69X9O3>VT<IZE<'ZJ2I
M_E6G4FP4444 %%%% !1110 4444 %%%% #2*R]>T%-838PPR\JW<'_ ]Q6M3
M=N: /&=5TJ337,4HP>Q[$>H/?^?K[TZ]GU+28]10Q2KD?J/<'_.>]>=:]X+E
MT[+QY>/U Y'U'I[C\J:9FXG.T4#_ #_GM_GBBF2%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7H/PS_U<O\
MOC^5>?5Z#\,_]7+_ +X_E0RH;G9T445)H%%%% !1110 4444 %%%% !1110
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M_P!Z3_OI?_B*/^%;6_\ >D_[Z7_XBBX<AYO17I'_  K:W_O2?]]+_P#$4?\
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MY/(SS7%&*]*_X5Q;>K_FO_Q-'_"N+;U?\U_^)HN'(SS7% %>E?\ "N+;U?\
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M]7_-?_B:/^%<6WJ_YK_\31<.1GFN*,5Z5_PKBV]7_-?_ (FC_A7%MZO^:_\
MQ-%PY&>:XHQ7I7_"N+;U?\U_^)H_X5Q;>K_FO_Q-%PY&>:XHQ7I7_"N+;U?\
MU_\ B:/^%<6WJ_YK_P#$T7#D9YKBC%>E?\*XMO5_S7_XFC_A7%MZO^:__$T7
M#D9YKBC%>E?\*XMO5_S7_P")H_X5Q;>K_FO_ ,31<.1GFN*,5Z5_PKBV]7_-
M?_B:/^%<6WJ_YK_\31<.1GFN*,5Z5_PKBV]7_-?_ (FC_A7%MZO^:_\ Q-%P
MY&>:XHQ7I7_"N+;U?\U_^)H_X5Q;>K_FO_Q-%PY&>:XHQ7I7_"N+;U?\U_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 26, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 26,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Denali Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3872213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">161 Oyster Point Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">866-8547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DNLI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001714899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="dnli-20260226.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="dnli-20260226.htm">dnli-20260226.htm</File>
    <File>dnli-20260226.xsd</File>
    <File>dnli-20260226_lab.xml</File>
    <File>dnli-20260226_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dnli-20260226.htm": {
   "nsprefix": "dnli",
   "nsuri": "http://www.denalitherapeutics.com/20260226",
   "dts": {
    "inline": {
     "local": [
      "dnli-20260226.htm"
     ]
    },
    "schema": {
     "local": [
      "dnli-20260226.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "dnli-20260226_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dnli-20260226_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.denalitherapeutics.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dnli-20260226.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dnli-20260226.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001714899-26-000020-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001714899-26-000020-xbrl.zip
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M,*F6!%E('J_&1/TP]/L4E$B"*D_Q5J74^N5GIV[;AT](:S^'%)^TCI4$,[D
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MK7G][TE[V2JLV6$85T[_(*CZ*Z*M_P-02P,$%     @ [X!:7&W\*U-F @
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M,^Z[C,!7^,V] SA9S%D"_@\PI@8X<5P4K@1<&T1S& 4<?@LM!R9V^HZ%B/?
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MV!B3]J+N8YHX:$_& _!@@&@0B(>SQ)XS6U2+!3Z0>U3+C)R10)4$R1099H(
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M<RFQIZH1"'LLM&\60&*"^?HW53&9Z"=5!)<79A>Z<]+A5D2K@M@#!LI2S 0
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MW5CUJKX]R[Z4A'MXA%MOF9K>7K78KDPP/?$0PX5#>XXKDDDB[AM&W+H=<A?
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MPVCD?O@O4$L! A0#%     @ [X!:7/=XBU<4$   5'<  !$
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M.3%P<F5S<W)E;&5A<V5Q-#(P,C4N:'1M4$L%!@     %  4 30$  $A%
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>dnli-20260226_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dnli-20260226.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <startDate>2026-02-26</startDate>
            <endDate>2026-02-26</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001714899</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2026-02-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Denali Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38311</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">46-3872213</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">161 Oyster Point Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">866-8547</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">DNLI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
